Drug Safety Settlement

A Ranbaxy office building is pictured in the northern Indian city of Mohali May 14, 2013. Indian generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the U.S. Department of Justice. The settlement is its largest-ever with a generic drugmaker over drug safety, according to the U.S. government. It includes $150 million in payments for a criminal fine and forfeiture and $350 million in payments for civil claims. REUTERS/Ajay Verma (INDIA - Tags: HEALTH BUSINESS)

Daiichi Sankyo says it was misled over Ranbaxy U.S. probes

Japanese drugmaker Daiichi Sankyo Co, which bought control of Ranbaxy Laboratories in 2008, said it believes unnamed former shareholders of the company hid information regarding U.S. regulatory probes into Ranbaxy.  Full Article 

  • Most Popular
  • Most Shared

REUTERS SHOWCASE

Bernanke Testimony

Bernanke Testimony

Bernanke says more progress needed before stimulus pullback.  Full Article 

Sensex Falls

Sensex Falls

Sensex falls for third day; L&T results spark worries.  Full Article 

Copper Shortage

Copper Shortage

Copper smelter closures put cable makers in tight spot.  Full Article 

Tax Avoidance

Tax Avoidance

Factbox: Apple, Amazon, Google and tax avoidance schemes.  Full Article 

Tracking India Gold

Tracking India Gold

Physical gold market awaits fresh import guidelines.  Full Article 

Earnings Season

Earnings Season

L&T looks overseas to offset weak home market  Full Article | Full Coverage 

Bank Acquisition

Bank Acquisition

Srei Infrastructure to buy Austrian bank unit - paper  Full Article 

Just Dial IPO

Just Dial IPO

Just Dial's 9.4 billion rupee IPO covered 11.6 times  Full Article 

Buy, Sell or Hold?

Buy, Sell or Hold?

Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade.  Full Coverage 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage 

JP Morgan, Barclays upgrade Infosys to overweight

Stocks

   
Track BSE Sectoral Indices

Track Markets: BSE Sectoral Indices

Track and analyse performance of all BSE sectoral indices and other global indices on a single page.   Full Coverage 

Employees walk in a forecourt at the Infosys campus in the Electronic City area of Bangalore September 4, 2012. REUTERS/Vivek Prakash/Files

Employees walk in a forecourt at the Infosys campus in the Electronic City area of Bangalore September 4, 2012.

Credit: Reuters/Vivek Prakash/Files

MUMBAI | Mon Jan 14, 2013 9:34am IST

MUMBAI (Reuters) - J.P.Morgan and Barclays Capital upgraded their ratings on Infosys to "overweight", citing an expected improvement in earnings after the software services exporter posted better-than-expected results and revenue outlook on Friday.

Barclays raised Infosys Ltd (INFY.NS) to "overweight" from "equal weight", while J.P.Morgan raised its rating from "neutral."

(Reporting by Abhishek Vishnoi and Rafael Nam; Editing by Subhranshu Sahu)
Top News
Business
Tech
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.